Scopus Biopharma Inc is a biotechnology company that focuses on the development of novel therapeutics for the treatment of autoimmune diseases, with a specific emphasis on rare and serious conditions. The company was founded in 2014 and is headquartered in Miami, Florida.
Scopus Biopharma is committed to leveraging its proprietary technology platform to discover and develop innovative therapies that address unmet medical needs in the field of autoimmune diseases. They work on identifying and targeting specific proteins and pathways that play a crucial role in the immune system's malfunction, leading to autoimmune disorders.
One of the company's key areas of focus is the development of a potential treatment for refractory Myasthenia Gravis, a rare and severe autoimmune neuromuscular disease. Their lead candidate, SCO-101, is an investigational product that has shown promise in preclinical studies for Myasthenia Gravis and is currently in clinical development.
Given the high unmet medical need and the potential for breakthrough therapies in the field of autoimmune diseases, Scopus Biopharma's efforts are closely watched by investors and stakeholders in the biotechnology and healthcare sectors. The company's dedication to advancing innovative treatments for rare autoimmune disorders has positioned it as a promising player in the biopharmaceutical industry.